YOKNEAM, Israel, March 3 /PRNewswire-FirstCall/ -- Lumenis(R) Ltd. (LUME.PK), a global developer, manufacturer and seller of laser and light- based devices for medical, aesthetic, ophthalmic, dental and veterinary applications, announced today the shipment of its 600th Lumenis One system, a major milestone for the Aesthetic industry. The Lumenis One is Lumenis' flagship platform for aesthetic light and laser treatments and is the most recent addition to Lumenis' family of IPL (Intense Pulsed Light) systems. Lumenis has provided thousands of IPL systems since it invented and first introduced IPL technology to the market in 1995.
Lumenis One represents the industry's only fourth generation of IPL technology and reinforces Lumenis' place at the forefront of perfecting IPL. Optimizing and building upon a firm clinical and technical foundation, Lumenis One unites four gold standard technologies on one multi-technology and multi- application platform: the Intense Pulsed Light for skin photorejuvenation and treating vascular and pigmented lesions, the LightSheer diode laser for hair removal, the Multi-Spot Nd:YAG for treating leg veins and deeper vascular lesions, and the Aluma with FACES(TM) technology for the treatment of wrinkles, fine lines and skin laxity. The system's key features include Optimal Pulse Technology (OPT), numerous presets, easy custom settings, and an intuitive touchscreen software interface. These enable Lumenis One to provide increased patient comfort, faster treatments, and easily tracked patient information.
Avner Raz, President and Chief Executive Officer, said, "Shipping the 600th Lumenis One since early 2004 clearly illustrates our success in advancing the technological state of the art in the Aesthetic market. Customer demand for the Lumenis One is strong around the world and clinical results have been good on all skin types. Lumenis continues to bring to market products that meet specific customer needs and provides direct benefit to their patients."
Dore Gilbert, MD, (Newport Beach, California) states, "In our practice there is no room for second best. With the Lumenis One, I know that my patients will have the best possible outcomes. The system is fast, powerful and able to treat difficult conditions such as rosacea and dispigmentation. The patient database, expert preset parameters and aggressive contact cooling means that I can delegate the procedures with confidence. My staff likes it so much that I have three of them operating continuously and am considering a fourth."
The Lumenis One with the new Aluma module will be featured at the upcoming 64th Annual Meeting of the American Academy of Dermatology to be held March 4 through 6 in San Francisco. The entire family of Lumenis aesthetic products will be displayed in the Lumenis booth at the AAD meeting. For more information about Lumenis' Aesthetic products, log onto http://www.aesthetic.lumenis.com
Investors: Lauri Hanover 1-866-232-6803 972-4-959-9122 About Lumenis
Lumenis is a global developer, manufacturer and seller of laser and light- based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto http://www.lumenis.com
The statements in this press release that are not historical facts are forward-looking statements which are subject to risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, the implementation and outcome of our Turnaround Plan, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company's international operations and the Company's ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation (including the Wells Notice recently received in which the staff indicated its intention to recommend that a civil proceeding be brought seeking, among other things, injunctive relief and civil monetary penalties) and several securities class action lawsuits to which the Company is subject and the outcome of the investigation conducted by the Audit Committee; uncertainties relating to the Company's continuing liquidity; uncertainties relating to the Company's lack of audited financial statements and other risks detailed from time to time in the reports filed by Lumenis with the SEC.
LumenisCONTACT: Investor, Lauri Hanover, +1-866-232-6803, +972-4-959-9122
